MedRes specializes in complex, minimally invasive surgical and interventional devices, providing comprehensive and flexible medical device design, development, and manufacturing services.

MedRes

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Maxwell Becton

Fairleigh Dickinson

Becton, Dickinson and Company

Encision develops and manufactures AEM® Shield™ Laparoscopic Surgical Instruments for improved patient safety in minimally invasive surgery, as per their self-described guidelines.

Encision

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Metric
Company Name	MedRes	Becton, Dickinson and Company	Encision	GE HealthCare Technologies Inc.
Symbol		BDX		GEHC
MSH ID	TECH:MEDRES	COM:BD	COM:ENCISION	COM:GEHEALTHCARE
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Medical - Instruments & Supplies	Medical Devices	Medical - Healthcare Information Services
Country	HU	US	US	US
Stage
Employee Count		70K		51K
Website	medres.tech	bd.com	encision.com	gehealthcare.com
LinkedIn		bd1		gehealthcare
Founders

Metric
Market Cap	64.70B	4.45M	36.12B
Enterprise Value
Monthly Web Traffic			1.37M
Web Traffic Growth			0.23
Valuation
Raised Capital			1.17B

Metric
Revenue	20.18B	19.55B
Revenue (LTM)
Revenue (NTM)
Gross Profit	20.18B	7.92B
EBITDA	2.42B	2.44B
Operating Income	2.42B	2.44B
Net Income	1.73B	3.10B
EPS	5.96	6.82
Diluted EPS	5.93	6.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.55	0.41
Operating Profit Margin	0.12	0.13
EBITDA Margin	0.12	0.12
Net Profit Margin	0.07	0.08
Return on Equity	0.06	0.22
Return on Assets	0.03	0.05
Return on Capital Employed	0.05	0.11

TECH:MEDRES

MedRes

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	54.49	19.27
P/B Ratio	2.70	4.68
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.63	2.15
EV Multiple	15.21	10.08

Metric
Days Sales Outstanding	42.45	84.00
Days Payables Outstanding		87.39
Days Inventory Outstanding	105.52	64.08
Operating Cycle	151.20	141.20
Cash Conversion Cycle	47.37	51.81
Asset Turnover	0.37	0.61

Metric
Operating Cash Flow	3.84B	2.10B
Free Cash Flow	3.12B	1.71B
Cash Flow to Debt	0.21	0.23
Operating Cash Flow/Sales	0.20	0.11
Free Cash Flow Yield	0.04	0.05

Metric
Cash & Equivalents	1.86B	2.50B
Accounts Receivable		-185M
Inventory	3.84B	1.96B
Goodwill	26.46B	12.94B
Debt to Capitalization	0.43	0.58
Debt to Assets	0.33	0.32
Current Ratio	1.08	1.25
Quick Ratio	1.36	0.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	-0.02
R&D to Revenue	0.06	0.06
SG&A to Revenue